OvaGene said this week that it has signed a licensing and collaboration agreement with the Moffitt Cancer Center to develop microRNAs as biomarkers for cancer drug response.

OvaGene said it now has the exclusive rights to to develop and commercialize assays based on miRNAs validated by Moffitt researcher Johnathan Lancaster. The company said it would initially focus on a test that can predict an ovarian cancer patient's response to treatment, and expects to have a product ready for market in 18 to 24 months.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A new report highlights the potential threats posed by advances in synthetic biology, NPR reports.

Johns Hopkins University's Steven Salzberg and his colleagues have come up with a new estimate for the number of human genes, Nature News reports.

A Bloomberg reporter tried to get her genetic data deleted, but found it's not so simple to do.

In Genome Research this week: study of intra-tumor heterogeneity, workflow resources for EPIGEN-Brazil, and more.

Jul
19
Sponsored by
Thermo Fisher Scientific

This webinar will discuss how ultra-highly sensitive and customizable targeted next-generation sequencing panels are applied in inherited disease research.